Skip to main content
OpenTrials
Completed

NCT Number: NCT00611611

BLYS and IFN in SLE

This protocol tests whether changes in BLyS or IFN can be detected in a normal immune response to a vaccine and, if so, whether the response differs between those with lupus and healthy controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Lupus Erythematosus Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Lupus Erythematosus, Systemic Skin and Connective Tissue Diseases

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ACR lupus criteria
  • 18<age<65

Exclusion criteria

  • chronic infection or cancer
  • pregnancy

Treatment and study plan

Fluzone

Biological

once

Pneumovax

Biological

once

Primary outcomes

  1. change in specific antibodies in response to vaccine

    Time frame: 2 weeks

Secondary outcomes

  1. change in BLyS after vaccination

    Time frame: 2 weeks

  2. change in IFN after vaccination

    Time frame: 2 weeks

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • Hospital for Special Surgery, New York

Registry information

Official study title

BLyS and IFN Responses to Antigen Challenge in Human SLE

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Feb 11, 2008
Registry last updated
Apr 28, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.